

Reference number
1755-H

SPECIALTY QUANTITY LIMIT PROGRAM

XALKORI (crizotinib)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Xalkori 200 mg capsules	60 per 30 days	250 mg twice daily
Xalkori 250 mg capsules		The following dosage adjustments may be necessary: - 200 mg twice daily - 250 mg once daily

III. REFERENCE

1. Xalkori [package insert]. New York, NY: Pfizer Inc.; January 2019.